MX2022012964A - Forma de dosificacion oral solida que comprende pomalidomida. - Google Patents

Forma de dosificacion oral solida que comprende pomalidomida.

Info

Publication number
MX2022012964A
MX2022012964A MX2022012964A MX2022012964A MX2022012964A MX 2022012964 A MX2022012964 A MX 2022012964A MX 2022012964 A MX2022012964 A MX 2022012964A MX 2022012964 A MX2022012964 A MX 2022012964A MX 2022012964 A MX2022012964 A MX 2022012964A
Authority
MX
Mexico
Prior art keywords
pomalidomide
dosage form
oral dosage
solid oral
dosage forms
Prior art date
Application number
MX2022012964A
Other languages
English (en)
Inventor
Serra João Pedro Silva
Marques Ramos Franco Frazão Joana Maria Fernandes
Original Assignee
Tecnimede Sociedade Tecnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal Sa filed Critical Tecnimede Sociedade Tecnico Medicinal Sa
Publication of MX2022012964A publication Critical patent/MX2022012964A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a la formulación de nuevas formas de dosificación farmacéuticas de pomalidomida para su uso terapéutico. La nueva forma de dosificación farmacéutica es una composición farmacéutica de liberación inmediata que comprende pomalidomida.
MX2022012964A 2020-04-15 2021-04-14 Forma de dosificacion oral solida que comprende pomalidomida. MX2022012964A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20169699 2020-04-15
PT11626120 2020-04-15
PCT/IB2021/053073 WO2021209919A1 (en) 2020-04-15 2021-04-14 Solid oral dosage form comprising pomalidomide

Publications (1)

Publication Number Publication Date
MX2022012964A true MX2022012964A (es) 2022-11-09

Family

ID=75919342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012964A MX2022012964A (es) 2020-04-15 2021-04-14 Forma de dosificacion oral solida que comprende pomalidomida.

Country Status (6)

Country Link
EP (1) EP4135668B1 (es)
BR (1) BR112022020897A2 (es)
CL (1) CL2022002778A1 (es)
CO (1) CO2022014548A2 (es)
MX (1) MX2022012964A (es)
WO (1) WO2021209919A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233849A1 (en) 2022-02-25 2023-08-30 KRKA, d.d., Novo mesto Pharmaceutical composition comprising pomalidomide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739802D1 (de) 1996-07-24 2010-04-22 Celgene Corp Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
EP3199149A1 (en) 2009-05-19 2017-08-02 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
CN104042590A (zh) * 2014-07-02 2014-09-17 南京卡文迪许生物工程技术有限公司 一种稳定的泊马度胺胶囊剂及其制备方法
EP3493791A1 (en) * 2016-08-02 2019-06-12 Synthon B.V. Pharmaceutical composition comprising pomalidomide
US10966971B2 (en) * 2017-02-18 2021-04-06 Natco Pharma Limited Pharmaceutical compositions of pomalidomide

Also Published As

Publication number Publication date
EP4135668A1 (en) 2023-02-22
BR112022020897A2 (pt) 2022-11-29
EP4135668B1 (en) 2024-04-17
WO2021209919A1 (en) 2021-10-21
CO2022014548A2 (es) 2022-11-08
CL2022002778A1 (es) 2023-05-05

Similar Documents

Publication Publication Date Title
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX394961B (es) Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
PH12021553056A1 (en) Modified release formulations and uses thereof
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
ZA202000028B (en) Use of vibegron to treat overactive bladder
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
MX2022012964A (es) Forma de dosificacion oral solida que comprende pomalidomida.
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
JOP20220319B1 (ar) أزيلاستين كعلاج مضاد للفيروسات
CO2024014215A2 (es) Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
MX2021008658A (es) Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).
PH12022550432A1 (en) Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and use thereof
ZA201908550B (en) Pharmaceutical compositions
WO2020055357A3 (en) Inhalation compositions comprising phosphodiesterase-4 inhibitor
WO2014014389A3 (ru) Композиция в форме геля для профилактики и лечения пародонта